The company was referred to us by the team of investment bankers at Jefferies. They wanted crisp and simple explanation of the mechanism of action of Werewolf’s novel approach to working with cytokines.

This was a presentation update project, where we take existing presentation structure, and – following the talk track of the presenter – simplify content and develop inforgraphics to help communicate the message. 

Werewolf Tx (Nasdaq: HOWL) has filed for $120M in an initial stock offering and had a successful launch on Nasdaq at the end of April 2021.